Souhaitez-vous accéder aux communiqués récents ?

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion...

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data...

• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes ...

Kailera Therapeutics, Inc., today reported financial results for the second quarter ended June 30, 2026.

Kailera Therapeutics, Inc., today announced the appointment of Nur Nicholson as Chief Technology Officer, effective August 31, 2026.

First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral...

LOS ANGELES, Aug. 06, 2026 (GLOBE NEWSWIRE) -- The 2026 Pet Innovation Awards today announced that PRIOME® Metabolic Health (MH) Postbiotic from ADM (NYSE: ADM), a global leader in innovative...

Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1™ trial is a Phase 1, randomized, controlled clinical trial...

MIRA reports positive 7-day dog study results for SKNY-1, supporting dose selection and advancement toward GLP toxicology studies.

Rising malnutrition among infants, oncology patients and older adults, along with healthcare investment and product advances, is driving market growth.